# OnCo record nepc-transformation (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/nepc-transformation/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "nepc-transformation" ;
  schema:name "Treatment-emergent neuroendocrine transformation (recognising it)"@en ;
  schema:alternateName "neuroendocrine transformation"@en, "NEPC"@en, "t-NEPC"@en, "CRPC-NE"@en, "small cell transformation prostate"@en, "neuroendocrine differentiation prostate"@en, "aggressive variant prostate cancer"@en ;
  schema:description "The test result that shows a prostate cancer has changed into a different, faster kind of cancer under hormone treatment. It is made on a biopsy, usually prompted by disease that is growing while the PSA stays flat."@en ;
  schema:url <https://onco.cc/biomarkers/nepc-transformation/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1097/PAS.0000000000000208>, <https://doi.org/10.1038/nm.4045>, <https://doi.org/10.1158/1078-0432.CCR-15-1259> ;
  onco:tag "biomarker", "resistance" ;
  onco:related <https://onco.cc/biomarkers/ar-amplification/>, <https://onco.cc/biomarkers/ar-v7-splice-variant/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-nepc/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/aurka/>, <https://onco.cc/targets/mycn/> ;
  onco:pathways <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/ar-signaling/> ;
  onco:terms <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/biopsy/>, <https://onco.cc/terms/psa/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014/>, <https://onco.cc/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/>, <https://onco.cc/key-papers/paper-beltran-nepc-aurka-mycn-cancer-discov-2011/>, <https://onco.cc/key-papers/paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016/>, <https://onco.cc/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/>, <https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/>, <https://onco.cc/key-papers/paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022/> .